Form 4: Apogee CFO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 1,500 shares of common stock for $75 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), disposed of 1,500 shares of common stock.
• The transaction occurred on December 4, 2025, at a price of $75 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on September 27, 2024.
• Following this transaction, Jane Henderson beneficially owns 194,871 shares of Apogee Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is generally considered a neutral event as it is not indicative of new information or a change in management's outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual officer's pre-planned stock sale.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal impact on shareholder sentiment, as it is a pre-scheduled event rather than a reaction to new company developments.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Transaction, Stock Sale, Jane Henderson, Chief Financial Officer, 10b5-1 Plan